ChromaDex Corporation (CDXC)

NASDAQ: CDXC · IEX Real-Time Price · USD
1.92
-0.19 (-9.00%)
At close: Jun 24, 2022 4:00 PM
2.00
+0.08 (4.17%)
After-hours: Jun 24, 2022 7:31 PM EDT
-9.00%
Market Cap 131.20M
Revenue (ttm) 70.03M
Net Income (ttm) -27.49M
Shares Out 68.33M
EPS (ttm) -0.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,541,093
Open 2.10
Previous Close 2.11
Day's Range 1.85 - 2.24
52-Week Range 1.51 - 10.78
Beta 1.78
Analysts Buy
Price Target 7.71 (+301.6%)
Earnings Date Aug 2, 2022

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of... [Read more...]

Industry Life Sciences Tools & Services
CEO Robert Fried
Employees 115
Stock Exchange NASDAQ
Ticker Symbol CDXC
Full Company Profile

Financial Performance

In 2021, ChromaDex's revenue was $67.45 million, an increase of 13.82% compared to the previous year's $59.26 million. Losses were -$27.13 million, 36.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for CDXC stock is "Buy." The 12-month stock price forecast is 7.71, which is an increase of 301.56% from the latest price.

Price Target
$7.71
(301.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and F...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ASN--ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™...

ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Si...

ChromaDex to Present at the Oppenheimer's 22nd Annual Consumer Growth and E-Commerce Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Oppenheimer--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presentin...

ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea. Juvenis is a Korean hea...

ChromaDex to Present at the LD Micro Invitational

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #LDMicro--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting vi...

ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China

ChromaDex Corp (NASDAQ: CDXC) has agreed to establish a joint venture through its wholly-owned subsidiary ChromaDex Asia Limited.  ChromaDex Asia is expected to assume the distribution agreement with Si...

ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the “...

ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex Externa...

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex Corporation Reports First Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022. First Quarter 2022 and Recent Highlights Total net sales ...

ChromaDex to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #financialresults--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs. May 12, 2022 at 4:30 p.m. ET to discuss its financial resu...

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #boardofdirectors--ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice ...

ChromaDex External Research Program (CERP™) Celebrates Over 250 Research Agreements With 235+ Researchers Around the ...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #MTA--ChromaDex Corp. (NASDAQ:CDXC) today celebrates over 250 material transfer agreements (MTAs) through the ChromaDex External Research Program (CERP™), featurin...

ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) today announced the company's latest product innovation with the U.S. launch of Tru Niagen® Immune, a first-of-its-kind combina...

ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IPNews--ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its global pate...

ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 27.27% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2021 financial results. Fourth Quarter 2021 and Recent Highlights Total net...

ChromaDex Shares Findings from First-Ever Peer-Reviewed Published Clinical Study Analyzing the Promising Effect of Ni...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #clinicalresearch--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study, as reported in the peer-reviewed journ...

ChromaDex to Report Fourth Quarter 2021 Financial Results on Wednesday, March 9, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. March 9, 2022 at 4:30 p.m. ET to discuss its financial results for t...

ChromaDex Announces Issuance of New U.S. Continuation Patent, Expanding Intellectual Property Portfolio for Nicotinam...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IPNews--ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted a continuation patent, adding to its global patent portfolio surrounding nicotinamide ri...

ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingre...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #niagen--ChromaDex Corp. (NASDAQ:CDXC) celebrates the ChromaDex External Research Program's (CERP™) 100th published peer-reviewed study on the company's flagship i...

ChromaDex Announces Results of New Pilot Clinical Trial Showing Anti-Inflammatory Effects of Nicotinamide Riboside (N...

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ClinicalResearch--ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or “NR...

ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements

ChromaDex Corp (NASDAQ:CDXC) has announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).  ChromaDex's propriet...

ChromaDex and Designs for Health Partner for New Product Development on Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements f...